Abiopharma

🔍 Parekh Kevan (Executive)

Company: Apple Inc. (AAPL)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 10,928 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 19,693.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,793 shares of Common Stock at $266.43 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 14,900.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,817 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,816.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 5,111 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,331.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4

Footnotes:

• F1: Each restricted stock unit ("RSUs") represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
• F2: Shares withheld by Apple to satisfy tax withholding requirements on vesting of restricted stock units. No shares were sold.
• F3: This award was granted on September 25, 2022. 12.5% of the award vested on April 15, 2023 and the remaining RSUs vest 12.5% in semi-annual installments over the four-year period ending October 15, 2026, subject to the terms and conditions of the underlying award agreement.
• F4: This award was granted on October 1, 2023. 12.5% of the award vested on April 15, 2024 and the remaining RSUs vest 12.5% in semi-annual installments over the four-year period ending October 15, 2027, subject to the terms and conditions of the underlying award agreement.